News

  • Report Spotlights Significant Progress Toward Achieving Company’s Environmental, Social and Governance Goals, Including Climate Pledge and DE&I Objectives MORRISVILLE, N.C., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions
    10.05.22
  • MORRISVILLE, N.C, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe and Chief Financial Officer Jason Meggs are scheduled to present at the 2022 Baird
    08.30.22
  • Revenue for the second quarter of $1,360.7 million increased 6.1% on a reported basis and 8.3% on a constant currency basis year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $947.4 million for the second quarter, a
    08.02.22
  • MORRISVILLE, N.C., July 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2022 financial results on Tuesday, August 2, 2022, prior to its earnings call at 9:00 a.m. ET.
    07.18.22
  • MORRISVILLE, N.C., May 24, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences. Chief Executive Officer Michelle Keefe and Chief Financial
    05.24.22
  • Healthcare Businesswomen’s Association Spotlights Kasey Boynton and Feni Komline for Biopharma Industry Impact MORRISVILLE, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Kasey Boynton,
    05.10.22
  • Alistair Macdonald to Retire After 20 Years in Variety of Leadership Roles Michael Brooks Named Chief Operating Officer Company Reports First Quarter 2022 Results and Updates Full Year Guidance MORRISVILLE, N.C., April 29, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully
    04.29.22
  • Highlights Revenue for the first quarter of $1,336.3 million increased 10.5% on a reported basis and 11.7% on a constant currency basis year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $1,241.9 million for the first
    04.29.22
  • MORRISVILLE, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the promotions of two senior internal leaders – Baba Shetty to President, Technology and Data Solutions, and Suma Ramadas to
    04.19.22
  • MORRISVILLE, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, will release its first quarter 2022 financial results on Friday, April 29th, 2022, prior to its
    04.11.22
  • Highlights Fourth quarter revenue of $1,373.4 million increased 20.5% year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $357.1 million for the fourth quarter, a year-over-year decline of 72.9% and a book-to-bill ratio
    02.17.22
  • MORRISVILLE, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, will release its fourth quarter and full year 2021 financial results on Thursday, February 17th, 2022,
    02.01.22
  • Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia Collaboration with Syneos Health to effectively reach the primary care
    01.26.22
  • MORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors.
    01.18.22
  • As Industry Dynamics Shift, Smaller Biotechnology Companies Will Continue to Drive Dealmaking in 2022 MORRISVILLE, N.C., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 12 th annual Dealmakers’
    01.11.22
  • MORRISVILLE, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 40 th
    01.04.22